DUBLIN, IRELAND--(Marketwire - July 19, 2007) -
Alltracel Announces a NanopeuticsTM Product and Technology Development License
Agreement with HemCon Medical Technologies to Serve the Military Market
Up front license fees and products expected to be on the market by 2008
Thursday, July 19th 2007: Dublin, Ireland and London, UK
Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the
Healthcare Innovation Group focused on the Woundcare, Oral Care, Dermal Health
and Cardiovascular Health markets, today announces its NanopeuticsTM subsidiary
has signed a licensing agreement for its technology with HemCon Medical
Technologies, Inc., the haemorrhage control market leaders in military markets.
Following the successful completion of product concept testing in the US and the
Czech Republic in Q2 NanopeuticsTM has agreed a technology development agreement
focused on Chitosan- based NanospiderTM technology for advanced woundcare
applications in all relevant markets.
An undisclosed license payment is payable immediately and will develop into a
royalty revenue model for the completed Chitosan-NanospiderTM products which are
expected to reach the market by 2008.
Commenting on the announcement, Tony Richardson, Alltracel's Chief Executive
Officer said;
"The NanopeuticsTM technology has been well received in the market place, and
today's announcement that HemCon Medical have decided to license our technology
underpins the full potential it offers. HemCon is the leading haemorrhage
control company serving the military markets and we are excited that we will be
working together with their team to bring the NanospiderTM technology to market
by 2008."
For Further Information Contact:
Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com
London: Deborah Scott Financial Dynamics: +44 207 831 3113
Alltracel, (AIM: AP.L) (
www.alltracel.com) the Healthcare Innovation Group is
focused on taking proprietary technology from research right through to
commercialisation in the global healthcare market.
Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a
public company which listed on London's Alternative Investment Market in July
2001.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial
office in London, England; R&D subsidiary in the Czech Republic and
manufacturing facilities in Shenzhen, China. Alltracel also has a wide network
of research, development and manufacturing partners in Europe, Asia and North
America.
Alltracel operates via two main divisions Alltracel Healthcare Group and
Alltracel Healthcare Technologies:
Alltracel Healthcare Group is focused on the commercialisation effort behind
proven innovative technologies and services for the global healthcare market.
Alltracel Healthcare Group has a range of stake holdings, joint ventures and
wholly owned business units operating in a variety of healthcare categories
including Wound Care, Oral Care, and Cardiovascular Health.
- Alltracel's specialist Oral Care subsidiary Westone (
www.westoneproducts.com)
is headquartered in London, England and is the leading contract supply and
manufacturing partner for the European private label inter-dental market.
Westone also partners with a number of leading oral care brands internationally.
- Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o.
(
www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is
dedicated to the commercialisation of NanospiderTM technology for the global
healthcare market.
Alltracel Healthcare Technologies specialises in innovation, research,
development and the deployment of proprietary technology in the global
healthcare market. Alltracel Healthcare Technologies has established a
substantial intellectual property portfolio with patents in a number of
healthcare applications areas such as Wound Care, Cardiovascular Health and Skin
Care.
m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc.
NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o.
This information is provided by RNS
The company news service from the London Stock Exchange